|
|
Bone Disease Treatment Market Research
 | |  |
| |
Global Information, Inc. offers market intelligence on every topic in the Bone Disease Treatment Market, including, but not limited to latest trend on thrapeutic of: Osteoporosis; Osteoarthritis; Rheumatoid Arthritis; Myeloma; Osteoarthropathy; Osteochondritis; OAP; OA; Bone Substitutes; Osteoanagenesis.
We offer market research, industry forecasts, and business analysis in the Bone Disease Treatment Market as well as other vertical industries. GII sells reports, databases, newsletters and annual information services that provide the latest market data, such as industry forecasts, projections, trends, market shares, research and development, sales and marketing strategies, and competitive analysis. The easiest way to find out if we have the information you need is to contact us right now. We are open 24 hours a day, 5 days a week with multiple language support. Please see our Contact page to see which office is open right now.
|
|
 | |  |
Reports
| Organ Transplant Immunosuppressive Markets |
|
| Published : 2007/12 |
| Most transplant patients require lifelong immunosuppressive therapy to prevent rejection, except when human leukocyte antigen (HLA)-identical transplants are used. The number of organ transplants performed worldwide is approximately 70,000 annually. As me ... |
| Brands & Strategies: Dyslipidemia |
|
| Published : 2007/09 |
| In 2006, the dyslipidemia market, valued at $27.7 billion in the US, Europe, and Japan, reached its peak for the near future. ... |
| Trial TRAX Rheumatoid Arthritis Clinical Trial Monitoring Brief |
|
| Published : 2007/09 |
| Austin Research Group' s Trial TRAX Clinical Intelligence Monitoring series provides detailed compilations and analysis of ongoing clinical studies within a specific therapeutic area or indication. Additionally, the Trial TRAX briefs contain synthesized b ... |
| Arthritis - US - June 2007 |
|
| Published : 2007/06 |
| This report covers the prevalence, incidence, costs, causes, prevention, and treatments of arthritis. Comprised of more than 100 distinct conditions, Arthritis affects approximately 50 million Americans. ... |
| Brands & Strategies: Psoriasis |
|
| Published : 2007/06 |
| Biologic therapies have had a major impact on the psoriasis market since the first such agent was approved by the FDA in 2003. In the moderate-to-severe psoriasis market, biologic agents alone totaled over $900 million in 2006. ... |
| Brands & Strategies: UA/NSTEMI |
|
| Published : 2007/06 |
| In 2006, the unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI) market, valued at more than $820 million in the United States, Europe, and Japan, was dominated by a handful of premium-priced therapies, including Schering-Plough' s gpIIb/II ... |
| European Osteoarthritis Markets |
|
| Published : 2007/06 |
| This Frost & Sullivan research service titled European Osteoarthritis Market provides an overview of current treatment options along with a complete analysis of key market drivers, restraints and trends prevailing in the market. ... |
| U.S. Multiple Myeloma Market |
|
| Published : 2007/03 |
| The U.S. Multiple Myeloma Market is a rapidly progressing field that is set to generate over $3 billion in revenue in the coming years. ... |
| Brands & Strategies: Rheumatoid Arthritis |
|
| Published : 2006/12 |
| The market for disease-modifying rheumatoid arthritis (RA) therapies is dominated by sales of three currently marketed tumor necrosis factor-alpha (TNF-alpha) inhibitors - Enbrel, Remicade, and Humira. ... |
| Brands & Strategies: Multiple Sclerosis |
|
| Published : 2006/09 |
| The market for multiple sclerosis (MS) therapies is dominated by a handful of key players-Biogen Idec, Serono, Schering AG, and Teva-who produce premium priced therapies including interferon-beta (Biogen Idec' s Avonex, Serono' s Rebif, and Schering AG' s ... |
| Rheumatoid Arthritis Therapeutics: Market Trends and R&D Insights |
|
| Published : 2006/09 |
| The market for rheumatoid arthritis therapeutics has experienced remarkably strong growth during the past five years due to the introduction of the biological response modifiers (BRMs) to treatment regimens. The value of this market will reach nearly $13 ... |
| New Drug Futures: Musculoskeletal |
|
| Published : 2006/05 |
| This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond in the musculoskeletal sector. ... |
| U.S and Western European Bone Graft Substitute Market |
|
| Published : 2005/06 |
| The U.S. and Western European Bone Graft report is presented as a Microsoft Powerpoint presentation (>180 slides) and contains more than 100 figures and tables that are ideal for marketing purposes. ... |
| U.S. Osteoporosis Therapeutics Markets |
|
| Published : 2005/01 |
| Despite the popularity of bisphosphonates in treating osteoporosis, there is room for improvement in terms of drug efficacy and shorter dosage regimens. ... |
| Japanese Markets for Trauma Devices |
|
| Published : 2004/12 |
| In 2004, the global trauma device market, comprising internal and external fi xation devices sold in the US, Europe, and Japan and was valued at over US $2 billion. The US market also includes long bone stimulation devices. By 2009, this market will grow ... |
| Orthopedic Drugs, Implants and Devices |
|
| Published : 2004/10 |
| The total orthopaedic drug, implant and device market is expected to reach $44 billion by end of 2004. Rising at an average annual growth rate (AAGR) of 11%, the market is expected to reach $74.1 billion by 2009. ... |
| U.S. Arthritis Therapies Markets |
|
| Published : 2004/05 |
| This Frost & Sullivan research service analyzes the key drivers and challenges influencing the U.S. arthritis therapies market. Product and pricing trends coupled with patient and revenue forecasts enable participants to formulate a structured marketing p ... |
| Regenerative Medicines: Bone and Joint Applications |
|
| Published : 2003/07 |
| This report focuses on the bone- and joint-related applications of and markets for the various types of regenerative medicine currently available and projected to be introduced during the forecast period (2001 to 2007). Market drivers discussed include an ... |
|
|
View Cart
